Skip to main content
BLRX
NASDAQ Life Sciences

BioLineRx Reports Potent GLIX1 Preclinical Data in Glioblastoma, Including TMZ-Resistant Models

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.11
Mkt Cap
$13.477M
52W Low
$2.15
52W High
$7.77
52W Position info
45% above low
Off High info
60% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

BLRX sits 45% above its 52-week low of $2.15.

Summary

BioLineRx announced new preclinical data for its lead asset GLIX1, showing potent anti-tumor effects in glioblastoma, including in models resistant to standard therapy, bolstering confidence in its ongoing clinical trial.


Key Events · Product Development and Regulatory · BLRX

  • Positive Preclinical GLIX1 Data

    New data demonstrates GLIX1's potent anti-tumor effect and robust efficacy in glioblastoma (GBM) across multiple in-vivo studies.

  • Efficacy in TMZ-Resistant Models

    GLIX1 showed a robust anti-tumor effect in temozolomide (TMZ)-resistant patient-derived xenograft (PDX) GBM models, where TMZ had no effect.

  • Supports Ongoing Clinical Trial

    The compelling results further support the recently initiated Phase 1/2a clinical trial evaluating GLIX1 for recurrent and progressive GBM.

  • Addresses High Unmet Need

    The data highlights GLIX1's potential to address the critical unmet need for GBM patients, especially those with limited response to TMZ.


Analysis · BLRX · Life Sciences

This 6-K filing provides highly encouraging new preclinical data for GLIX1, BioLineRx's lead asset, demonstrating strong anti-tumor effects in glioblastoma (GBM), particularly in temozolomide (TMZ)-resistant models. This data significantly strengthens the scientific rationale for the ongoing Phase 1/2a clinical trial for GLIX1, especially given the high unmet medical need in GBM and the company's previously disclosed "going concern" warning. Positive data like this is crucial for a micro-cap biotech to attract further investment and de-risk its pipeline.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BLRX was trading at $3.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $2.15 to $7.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLRX - Latest Insights

BLRX
Oct 02, 2026, 5:00 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $2.37
Real-time Price: $1.40 info
Change: -$0.970 (-41%) info
Market Cap: $9.185M info
BLRX
Sep 10, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.22
Real-time Price: $1.40 info
Change: -$0.820 (-37%) info
Market Cap: $9.185M info
BLRX
Aug 31, 2026, 11:19 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $2.74
Real-time Price: $1.40 info
Change: -$1.34 (-49%) info
Market Cap: $9.185M info
BLRX
Aug 31, 2026, 10:23 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.69
Real-time Price: $1.40 info
Change: -$1.29 (-48%) info
Market Cap: $9.185M info
BLRX
Aug 31, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.73
Real-time Price: $1.40 info
Change: -$1.33 (-49%) info
Market Cap: $9.185M info